Tobramycin inhaled products (Tobi, Tobi Podhaler, Bethkis, Kitabis Pak)

Tobramycin inhaled products (Tobi, Tobi Podhaler, Bethkis, Kitabis Pak) are covered for cystic fibrosis and for non‑CF bronchiectasis only when airway cultures document Pseudomonas aeruginosa and are excluded without culture evidence or outside these indications. Approval requires prescription by or consultation with a pulmonologist (or a CF specialist for CF), documented positive airway culture (age ≥18 for non‑CF bronchiectasis), dosing limited to 300 mg nebulized twice daily on a 28‑day on/28‑day off cycle, and is authorized up to 12 months.

"Management of cystic fibrosis in individuals with Pseudomonas aeruginosa."

Sign up to see full coverage criteria, indications, and limitations.